BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/15/2020 8:19:14 AM | Browse: 840 | Download: 1371
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 54822
Country China
Received
2020-02-20 08:58
Peer-Review Started
2020-02-20 09:00
To Make the First Decision
Return for Revision
2020-04-18 21:27
Revised
2020-05-08 18:23
Second Decision
2020-05-25 07:20
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2020-05-27 19:00
Articles in Press
2020-05-27 19:00
Publication Fee Transferred
Edit the Manuscript by Language Editor
2020-05-31 23:47
Typeset the Manuscript
2020-06-12 01:55
Publish the Manuscript Online
2020-06-15 08:19
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Observational Study
Article Title Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma
Manuscript Source Unsolicited Manuscript
All Author List Bao-Jiang Liu, Song Gao, Xu Zhu, Jian-Hai Guo, Xin Zhang, Hui Chen, Xiao-Dong Wang and Ren-Jie Yang
ORCID
Author(s) ORCID Number
Bao-Jiang Liu http://orcid.org/0000-0001-8180-7698
Song Gao http://orcid.org/0000-0002-7466-3654
Xu Zhu http://orcid.org/0000-0001-9983-5048
Jian-Hai Guo http://orcid.org/0000-0001-6700-0978
Xin Zhang http://orcid.org/0000-0001-9035-1442
Hui Chen http://orcid.org/0000-0001-8541-2167
Xiao-Dong Wang http://orcid.org/0000-0003-1013-9308
Ren-Jie Yang http://orcid.org/0000-0002-9954-4395
Funding Agency and Grant Number
Funding Agency Grant Number
Foundation of Chinese Geriatric Oncology Society CGOS-01-2012-1-00800
Corresponding Author Xu Zhu, MD, PhD, Chief Doctor, Full Professor, Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), No. 52, Fucheng Road, Haidian District, Beijing 100142, China. drzhuxu@163.com
Key Words Hepatocellular carcinoma; Transcatheter arterial chemoembolization; Hepatic arterial infusion chemotherapy; Oxaliplatin; Fluorouracil; Sorafenib
Core Tip oth hepatic arterial infusion chemotherapy (HAIC) and sorafenib plus transcatheter arterial chemoembolization (TACE) combination therapy are widely used as a treatment of choice in patients with hepatocellular carcinoma (HCC) in Asia. However, the safety and efficacy of sorafenib combined with HAIC (folinic acid, 5-fluorouracil and oxaliplatin) after TACE for intermediate and advanced HCC have not been firmly established. In the present study, we confirmed the treatment efficacy and safety of this combination therapy. We believe that this study can help doctors and patients to select appropriate therapy.
Publish Date 2020-06-15 08:19
Citation Liu BJ, Gao S, Zhu X, Guo JH, Zhang X, Chen H, Wang XD, Yang RJ. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(6): 663-676
URL https://www.wjgnet.com/1948-5204/full/v12/i6/663.htm
DOI https://dx.doi.org/10.4251/wjgo.v12.i6.663
Full Article (PDF) WJGO-12-663.pdf
Full Article (Word) WJGO-12-663.docx
STROBE Statement 54822-STROBE-Statement-revision.pdf
Manuscript File 54822-Review_WangTQ.docx
Answering Reviewers 54822-Answering reviewers.pdf
Audio Core Tip 54822-Audio core tip.mp3
Biostatistics Review Certificate 54822-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form 54822-Conflict-of-interest statement.pdf
Copyright License Agreement 54822-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s) 54822-Grant application form(s).pdf
Signed Informed Consent Form(s) or Document(s) 54822-Informed consent statement.pdf
Institutional Review Board Approval Form or Document 54822-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate 54822-Language certificate.pdf
Peer-review Report 54822-Peer-review(s).pdf
Scientific Misconduct Check 54822-Bing-Tang JZ-1.png
Scientific Misconduct Check 54822-Bing-Yan JP-2.png
Scientific Misconduct Check 54822-Scientific misconduct check.pdf
Scientific Editor Work List 54822-Scientific editor work list.pdf